ONCY
Income statement / Annual
Last year (2024), Oncolytics Biotech Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Oncolytics Biotech Inc.'s net income was -$31.71 M.
See Oncolytics Biotech Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$403.00 K
|
$392.00 K
|
$452.07 K
|
$446.19 K
|
$485.57 K
|
$95.38 K
|
$90.77 K
|
$162.23 K
|
$180.41 K
|
| Gross Profit |
$0.00
|
-$403.00 K
|
-$392.00 K
|
-$452.07 K
|
-$446.19 K
|
-$485.57 K
|
-$95.38 K
|
-$90.77 K
|
-$162.23 K
|
-$180.41 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$21.65 M
|
$17.71 M
|
$15.43 M
|
$12.92 M
|
$12.94 M
|
$11.13 M
|
$9.42 M
|
$9.39 M
|
$9.77 M
|
$8.60 M
|
| General & Administrative Expenses |
$13.34 M
|
$16.08 M
|
$11.49 M
|
$13.32 M
|
$12.51 M
|
$0.00
|
$0.00
|
$0.00
|
$5.36 M
|
$5.14 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
-$452.49 K
|
-$445.69 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.34 M
|
$16.08 M
|
$11.49 M
|
$12.86 M
|
$12.07 M
|
$8.84 M
|
$7.08 M
|
$6.21 M
|
$5.36 M
|
$5.14 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$13.31 M
|
$12.51 M
|
$9.56 M
|
$7.24 M
|
$6.21 M
|
$162.23 K
|
$180.41 K
|
| Operating Expenses |
$34.98 M
|
$33.79 M
|
$26.92 M
|
$26.23 M
|
$25.46 M
|
$20.69 M
|
$16.66 M
|
$15.61 M
|
$15.29 M
|
$13.92 M
|
| Cost And Expenses |
$34.98 M
|
$33.79 M
|
$26.92 M
|
$26.23 M
|
$25.46 M
|
$20.69 M
|
$16.66 M
|
$15.61 M
|
$15.29 M
|
$13.92 M
|
| Interest Income |
$0.00
|
$1.33 M
|
$528.00 K
|
$98.61 K
|
$121.19 K
|
$179.28 K
|
$173.50 K
|
$130.10 K
|
$163.90 K
|
$197.86 K
|
| Interest Expense |
$0.00
|
$0.00
|
$528.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$102.00 K
|
$81.00 K
|
$392.00 K
|
$452.07 K
|
$446.19 K
|
$485.57 K
|
$95.38 K
|
$90.77 K
|
$162.23 K
|
$180.41 K
|
| EBITDA |
-$34.88 M |
-$33.71 M |
-$26.83 M |
-$25.66 M |
-$25.37 M |
-$20.02 M |
-$17.18 M |
-$15.51 M |
-$15.13 M |
-$13.74 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.40 M
|
$6.14 M
|
$2.17 M
|
-$20.06 K
|
$2.95 M
|
-$12.43 M
|
$173.50 K
|
$130.10 K
|
$163.90 K
|
$197.86 K
|
| Income Before Tax |
-$31.58 M
|
-$27.66 M
|
-$24.75 M
|
-$26.25 M
|
-$22.51 M
|
-$33.12 M
|
-$16.49 M
|
-$15.48 M
|
-$15.13 M
|
-$13.72 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$130.00 K
|
$97.00 K
|
$84.00 K
|
$49.43 K
|
-$2.95 M
|
$12.43 M
|
$548.04 K
|
$141.50 K
|
$9.37 K
|
$3.15 K
|
| Net Income |
-$31.71 M
|
-$27.75 M
|
-$24.84 M
|
-$26.30 M
|
-$19.55 M
|
-$45.55 M
|
-$17.04 M
|
-$15.62 M
|
-$15.14 M
|
-$13.72 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.41 |
-0.41 |
-0.43 |
-0.49 |
-0.48 |
-2.06 |
-1.06 |
-1.12 |
-1.2 |
-1.16 |
| EPS Diluted |
-0.41 |
-0.41 |
-0.43 |
-0.49 |
-0.48 |
-2.06 |
-1.06 |
-1.12 |
-1.2 |
-1.16 |
| Weighted Average Shares Out |
$76.48 M
|
$67.62 M
|
$58.03 M
|
$53.51 M
|
$40.34 M
|
$22.14 M
|
$16.02 M
|
$13.94 M
|
$12.62 M
|
$11.85 M
|
| Weighted Average Shares Out Diluted |
$76.48 M
|
$67.62 M
|
$58.03 M
|
$53.51 M
|
$40.34 M
|
$22.14 M
|
$16.02 M
|
$13.94 M
|
$12.62 M
|
$11.85 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
